Stocktoria
Vaxcyte, Inc. PCVX
Vaxcyte, Inc. financials (annual)
Bars are annual figures from 2019 to 2025; red bars are negative (a loss or cash outflow).
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| R&D expense | $794.3M | $476.6M | $332.3M | $169.5M | $78.4M | $73.6M | $45.6M |
| Operating income | -$923.7M | -$569.5M | -$468.0M | -$232.3M | -$103.7M | -$89.6M | -$54.2M |
| Interest expense | — | — | $0 | $2,000 | $7,000 | $7,000 | $40,000 |
| Income tax | $0 | $0 | $0 | — | — | — | — |
| Net income | -$766.6M | -$463.9M | -$402.3M | -$223.5M | -$100.1M | -$89.2M | -$50.3M |
| EPS (diluted) | $-5.63 | $-3.80 | $-4.14 | $-3.44 | $-1.93 | $-3.02 | — |
| Operating cash flow | -$655.6M | -$452.6M | -$296.8M | -$170.6M | -$121.4M | -$46.6M | -$47.1M |
| Free cash flow | -$669.3M | -$475.1M | -$312.9M | -$176.4M | -$127.9M | -$47.8M | -$48.3M |
| Cash & equivalents | $174.0M | $387.9M | $397.5M | $834.7M | $69.0M | $386.2M | $59.0M |
| Total assets | $3.0B | $3.5B | $1.4B | $1.0B | $324.3M | $392.8M | $65.7M |
| Total liabilities | $317.2M | $205.5M | $167.4M | $52.6M | $40.3M | $47.0M | $11.8M |
| Shareholders' equity | $2.7B | $3.3B | $1.2B | $953.6M | $284.0M | $345.8M | -$106.4M |
Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.